Codex is empowering researchers with the tools and resources they need to develop vaccines, therapeutics, and diagnostics for the SARS-CoV-2 virus
Harnessing the power of synthetic biology to combat COVID-19
View our webinar with Dr. Dan Gibson and team, as they discuss how to effectively “print” the genome required to create vaccines and therapeutics to combat COVID-19.
The spread of COVID-19
The coronavirus outbreak originated in Wuhan, China, in late 2019 and has spread to at least 155 countries since then, mutating at most every stop.
How SARS-CoV-2 has mutated
The coronavirus, like all viruses, is undergoing small changes in its genome as it spreads, creating a shifting battleground in the creation of diagnostics, therapeutics and vaccines.
This challenge has been further complicated as, according to the New York Times, labs are “now facing potential shortages of key materials… needed to run tests for the novel coronavirus.”
Codex is here to address the shortage with the BioXp™ system, a DNA printer that can produce the parts for the entire ~30kb genome of SARS-CoV-2 (the causal agent of COVID-19) in a single overnight run, supporting development of diagnostics, therapeutics and vaccines. Read the app note
Defeat COVID-19 and whatever might come next
For vaccine developers, the BioXp™ system can rapidly generate — in a single overnight run — multiple iterations of the antigens (such as the spike protein) and synthesize rationally designed mutated genome parts to enable the development of DNA vaccines, RNA vaccines and live attenuated vaccines.